[go: up one dir, main page]

MX2020001337A - Formulaciones que comprenden un acido nucleico en una alta concentracion. - Google Patents

Formulaciones que comprenden un acido nucleico en una alta concentracion.

Info

Publication number
MX2020001337A
MX2020001337A MX2020001337A MX2020001337A MX2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A
Authority
MX
Mexico
Prior art keywords
treatment
nucleic acid
formulations
high concentration
viscosity
Prior art date
Application number
MX2020001337A
Other languages
English (en)
Inventor
Mariana Dimitrova
William J Bennett
Qi Wang
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2020001337A publication Critical patent/MX2020001337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las composiciones de ácido nucleico de baja viscosidad y alta concentración que pueden administrarse mediante múltiples vías parenterales podrían permitir una dosificación menos frecuente que los productos de ácido nucleico que se encuentran presentes en la actualidad en el mercado. En particular, las formulaciones de desfibrotides de baja viscosidad para la administración subcutánea, intramuscular e intraperitoneal son más convenientes para el paciente y/o se administran fuera del entorno hospitalario. Las formulaciones de la invención pueden utilizarse en el tratamiento de numerosas afecciones lo que incluye, por ejemplo, el tratamiento de arteriopatías periféricas, el tratamiento de insuficiencia renal aguda, el tratamiento de isquemia miocárdica aguda y el tratamiento y prevención del síndrome de obstrucción sinusoidal o VOD.
MX2020001337A 2017-08-03 2018-08-03 Formulaciones que comprenden un acido nucleico en una alta concentracion. MX2020001337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540657P 2017-08-03 2017-08-03
PCT/US2018/045152 WO2019028340A1 (en) 2017-08-03 2018-08-03 FORMULATIONS COMPRISING A HIGH CONCENTRATION NUCLEIC ACID

Publications (1)

Publication Number Publication Date
MX2020001337A true MX2020001337A (es) 2020-09-09

Family

ID=63364168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001337A MX2020001337A (es) 2017-08-03 2018-08-03 Formulaciones que comprenden un acido nucleico en una alta concentracion.

Country Status (16)

Country Link
US (2) US20200261489A1 (es)
EP (1) EP3661484A1 (es)
JP (1) JP2020530004A (es)
KR (1) KR20200121780A (es)
CN (1) CN111132663A (es)
AR (1) AR112403A1 (es)
AU (1) AU2018309068A1 (es)
BR (1) BR112020002289A2 (es)
CA (1) CA3071544A1 (es)
CO (1) CO2020001873A2 (es)
IL (1) IL272405A (es)
MX (1) MX2020001337A (es)
SG (1) SG11202000952PA (es)
TW (1) TW201909904A (es)
WO (1) WO2019028340A1 (es)
ZA (1) ZA202000676B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019213053A1 (en) 2018-04-30 2019-11-07 Gentium S.R.L. Methods for treating patients having sinusoidal obstruction syndrome
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
WO2021212055A1 (en) 2020-04-17 2021-10-21 Jazz Pharmaceuticals Ireland Limited Defibrotide treatment for the prevention of organ rejection and injury
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome
KR20220151414A (ko) * 2021-05-06 2022-11-15 연세대학교 산학협력단 허혈성 뇌질환 예방 또는 치료용 약학적 조성물
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US4693134A (en) 1985-06-20 1987-09-15 Excelermatic Inc. High-powered vehicle drive train
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
IT1223322B (it) 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE69928778T2 (de) 1999-06-08 2006-07-06 Gentium S.P.A., Villa Guardia Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1325962A1 (en) 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
MX2007010407A (es) 2005-03-03 2007-10-17 Gentium Spa Formulacion con accion anti-tumor.
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
CN101301308A (zh) * 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防弥散性血管内凝血药物中的应用
CN101301306A (zh) * 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防休克药物中的应用
CN101759767A (zh) 2008-10-23 2010-06-30 湖州来色生物基因工程有限公司 一种双甘氨肽的合成方法
AU2011223805B2 (en) * 2010-03-01 2015-10-29 Cytodyn Inc. Concentrated protein formulations and uses thereof
CN103260627A (zh) 2010-11-12 2013-08-21 真蒂奥姆有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Also Published As

Publication number Publication date
SG11202000952PA (en) 2020-02-27
CN111132663A (zh) 2020-05-08
KR20200121780A (ko) 2020-10-26
US20210338707A1 (en) 2021-11-04
WO2019028340A1 (en) 2019-02-07
US20200261489A1 (en) 2020-08-20
IL272405A (en) 2020-03-31
BR112020002289A2 (pt) 2020-07-28
EP3661484A1 (en) 2020-06-10
AU2018309068A1 (en) 2020-02-20
AU2018309068A8 (en) 2020-02-27
CA3071544A1 (en) 2019-02-07
JP2020530004A (ja) 2020-10-15
ZA202000676B (en) 2021-01-27
AR112403A1 (es) 2019-10-23
TW201909904A (zh) 2019-03-16
CO2020001873A2 (es) 2020-04-13
WO2019028340A9 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2020001337A (es) Formulaciones que comprenden un acido nucleico en una alta concentracion.
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
MY187047A (en) Selective pyy compounds and uses thereof
MA43574A (fr) Compositions ayant des amplificateurs de perméation pour l'administration de médicaments
MX389802B (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
TN2018000056A1 (en) Rapid-acting insulin compositions.
MX376379B (es) Metodos para tratar dolor usando dimeros de acetominofeno farmaceuticamente activos enlazados a traves de grupos hidroxilo fenolicos
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
JOP20200004A1 (ar) تركيبات طويلة المفعول
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MD20180049A2 (ro) Compoziţie farmaceutică
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
MX2020000374A (es) Maltodextrinas entrelazadas para el suministro oral de activos biológicos.
MD20170071A2 (ro) Compoziţii injectabile de paracetamol
MX2017016978A (es) Composicion farmaceutica de heparinas de bajo peso molecular.
NZ723139A (en) Fgf-18 compound dosing regimen
WO2016115442A3 (en) Therapeutic protein formulations
NZ723139B2 (en) Fgf-18 compound dosing regimen
Sharma Bisphosphonates increase the risk of atrial fibrillation
PH12017500345A1 (en) Pharmaceutical composition for the treatment of acute tooth or jaw pain